Table 2 The anti-cancer properties of some typical GLP compounds
From: A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer
GLP | Cancer | Anti-cancer mechanisms | Refs. | |||
|---|---|---|---|---|---|---|
Inhibiting proliferation | Inducing apoptosis | Inhibiting metastasis | Regulating autophagy | |||
FYGL | Pancreatic cancer | − |  +  | − |  +  | [57] |
WSG | Tongue cancer | − |  +  | − | − | [58] |
WSG | Lung cancer | − | − |  +  | − | [13] |
SeGLP-2B-1 | Breast cancer |  +  |  +  | − | − | [59] |
(1,3)-β-D-Glucan derivative | Lymphoma |  +  | − | − | − | [60] |
LZP-F3 | Leukemia | − |  +  | − | − | [61] |
LZP-F3 | Urothelial carcinoma | − |  +  | − | − | [62] |
SCGLP1 | Osteosarcoma |  +  |  +  | − | − | [63] |
GL-IV-I | Sarcoma |  +  |  +  | − | − | [64] |
Ganoderan B | NSCLC | − |  +  |  +  | − | [65] |
Ganopoly | Cancer |  +  |  +  | − | − | [66] |
SeGLP-2B-1 | Cancer |  +  | − | − | − | [67] |
GLP-1–1 | Cancer |  +  | − | − | − | [68] |
β-glucan | Colon cancer |  +  | − | − | − | [69] |